EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Randomisierte kontrollierte StudieOpen Access · CC BY-NC-ND 4.0

Randomized Phase I Trial of the α‐Synuclein Antibody Lu AF82422

Louise Buur iD, Jonas Wiedemann, Frank Larsen, Fayrouz Ben Alaya-Fourati, Pekka Kallunki, Dorte Kornerup Ditlevsen, Mette Høgh Sørensen, Didier Meulien

Movement Disorders · 2024-06 · 39 (6) · 936-944

DOI: 10.1002/mds.29784 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift Movement Disorders, online erschienen am 17.03.2024. Verfasst von Louise Buur und 7 weiteren Autor:innen. Beteiligte Einrichtung: H. Lundbeck A/S, Copenhagen, Denmark. Hauptthemen laut MEDLINE: alpha-Synuclein, Parkinson Disease. Die Arbeit wurde bisher 51-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: H. Lundbeck A/S.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Immunotherapy targeting pathological α‐synuclein (α‐syn) species is a promising strategy for slowing disease progression in neurodegenerative synucleinopathies, including Parkinson's disease (PD).

Objective

The aim was to evaluate the safety, tolerability, pharmacokinetics, and target engagement of ascending doses of Lu AF82422.

Methods

In this first‐in‐human study (NCT03611569), healthy participants (18–55 years, cohort A) and patients with PD (40–80 years, Hoehn and Yahr stage ≤3, cohort B) were enrolled in ascending‐dose cohorts and randomly assigned to receive single intravenous infusions of Lu AF82422 (cohorts A1–A6: 75, 225, 750, 2250 4500, and 9000 mg, respectively; cohorts B1 and B2: 2250 and 9000 mg, respectively) or placebo. Participants were monitored during a 12‐week observational period.

Results

Overall, single intravenous infusions of Lu AF82422 were safe and well tolerated, and no serious adverse events (AE) were observed; the most common AEs were related to the study on lumbar punctures, headache, and common infections. Lu AF82422 concentrations (in plasma and cerebrospinal fluid [CSF]) increased in a dose‐proportional manner with no observable differences between cohorts; mean plasma half‐life was 700 h. Plasma concentrations of Lu AF82422 had an immediate, concentration‐dependent lowering effect on the plasma concentration of free α‐syn and on the ratio of free to total α‐syn in all cohorts and lowered the free‐to‐total α‐syn ratio in CSF in the high‐dose PD cohort.

Conclusions

The safety and pharmacokinetic profile of Lu AF82422 were appropriate for further clinical development, and results indicated peripheral target engagement. The central target engagement observed in participants with PD indicates that the doses of Lu AF82422 tested may provide CSF concentrations sufficient to target aggregated forms of α‐syn. © 2024 H. Lundbeck A/S. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

alpha-SynucleinParkinson DiseaseHumansMiddle AgedMaleFemaleAdultAgedAdolescentYoung AdultAged, 80 and overDose-Response Relationship, DrugDouble-Blind Method

Stichwörter der Autor:innen

Lu AF82422monoclonal antibodypharmacokineticssafetyα‐synuclein

Substanzen

alpha-Synuclein

Autor:innen und Institutionen

  • H. Lundbeck A/S, Copenhagen, Denmark.

ORCID-Profile: Louise Buur

Förderung

  • H. Lundbeck A/S

Zitieren

APA

Buur, L., Wiedemann, J., Larsen, F., Ben Alaya-Fourati, F., Kallunki, P., Ditlevsen, D. K., Sørensen, M. H., & Meulien, D. (2024). Randomized Phase I Trial of the α‐Synuclein Antibody Lu AF82422. Movement Disorders, 39(6), 936-944. https://doi.org/10.1002/mds.29784

Vancouver

Buur L, Wiedemann J, Larsen F, Ben Alaya-Fourati F, Kallunki P, Ditlevsen DK, et al. Randomized Phase I Trial of the α‐Synuclein Antibody Lu AF82422. Movement Disorders. 2024;39(6):936-944. doi:10.1002/mds.29784

BibTeX
@article{Buur2024,
  author = {Buur, Louise and Wiedemann, Jonas and Larsen, Frank and Ben Alaya-Fourati, Fayrouz and Kallunki, Pekka and Ditlevsen, Dorte Kornerup and Sørensen, Mette Høgh and Meulien, Didier},
  title = {Randomized Phase I Trial of the α‐Synuclein Antibody Lu AF82422},
  journal = {Movement Disorders},
  year = {2024},
  volume = {39},
  number = {6},
  pages = {936--944},
  doi = {10.1002/mds.29784}
}
Kostenlos starten →